Follow us on Twitter
twitter icon@FreshPatents


Nucleotide patents

      

This page is updated frequently with new Nucleotide-related patent applications.




 Methods for non-invasive prenatal ploidy calling patent thumbnailMethods for non-invasive prenatal ploidy calling
Disclosed herein are methods for determining the copy number of a chromosome in a fetus in the context of non-invasive prenatal diagnosis. In an embodiment, the measured genetic data from a sample of genetic material that contains both fetal dna and maternal dna is analyzed, along with the genetic data from the biological parents of the fetus, and the copy number of the chromosome of interest is determined.
Natera, Inc.


 Methods and systems for cell state quantification patent thumbnailMethods and systems for cell state quantification
Systems, methods, libraries, kits, and computer software tools are provided for designing and producing engineered cells. Such engineered cells can be used for cell state quantification, such as genome, transcriptome and/or proteome quantification.
Ginkgo Bioworks, Inc.


 Method for differentiating between lung squamous cell carcinoma and lung adenocarcinoma patent thumbnailMethod for differentiating between lung squamous cell carcinoma and lung adenocarcinoma
Provided is an approach for differentially determining the histological type of a lung cancer lesion objectively and rapidly with high accuracy. A method for differentially assessing a lesion in a lung cancer patient as squamous cell carcinoma or adenocarcinoma, comprising a step of measuring an expression level of an expression product of at least one dna comprising a transcription start site in a biological sample collected from the lesion, wherein the dna comprises a base at an arbitrary position in the transcription start site and at least one or more bases located immediately downstream thereof in any of nucleotide sequences represented by seq id nos: 1 to 213, and the transcription start site is a region wherein both ends thereof are defined by the first base and the 101st base counted from the 3′ end in any of the nucleotide sequences represented by seq id nos: 1 to 213..
Riken


 Methods of fetal abnormality detection patent thumbnailMethods of fetal abnormality detection
Methods and kits for selectively enriching non-random polynucleotide sequences are provided. Methods and kits for generating libraries of sequences are provided.
Verinata Health, Inc.


 Nucleotide analogs for real-time sequencing  single molecule patent thumbnailNucleotide analogs for real-time sequencing single molecule
This invention is to describe nucleotide analogs used in a method for the determination of a nucleic acid sequence. The method involves an enzyme, an enzyme complex or plural number of enzymes with more than one enzymatic activity and a set of nucleotide analogs, to achieve high signal readout accuracy in nucleic acid sequencing by making each signal to have a long signaling time span which allows a higher signal clarity..
Personal Genomics, Inc.


 Detection of target nucleic acid sequences by pto cleavage and extension assay patent thumbnailDetection of target nucleic acid sequences by pto cleavage and extension assay
The present invention relates to the detection of a target nucleic acid sequence by a ptoce (pto cleavage and extension) assay. The present invention detects a target nucleic acid sequence in which the pto (probing and tagging oligonucleotide) hybridized with the target nucleic acid sequence is cleaved to release a fragment and the fragment is hybridized with the cto (capturing and templating oligonucleotide) to form an extended duplex, followed by detecting the presence of the extended duplex.
Seegene, Inc.


 Fluorous oligonucleotide microarray patent thumbnailFluorous oligonucleotide microarray
A fluorous-modified composition, a fluorous nucleoside, nucleotide, or oligonucleotide microarray, a compositional detection process, a process of forming a fluorous nucleoside, nucleotide, or oligonucleotide microarray, and fluorous nucleoside, nucleotide, or oligonucleotide microarray processes are disclosed. The fluorous-modified composition includes a linker, a nucleoside, nucleotide, or oligonucleotide connected to the linker, and a fluorous domain connected to the linker.
Ms+hu 2 +l Array Llc


 Nucleic acid amplificiation techniques and methods for detecting bacterial infection patent thumbnailNucleic acid amplificiation techniques and methods for detecting bacterial infection
Sequence specific dna amplification and analysis techniques are provided. In some aspects, methods of the embodiments comprise amplifying sequence from two regions of a target sequence in the presence of a blocking oligonucleotide (e.g., such as a phosphorothioate-containing oligonucleotide) that hybridizes to the target sequence between the two regions.
Board Of Regents, The University Of Texas System


 Diagnostic for sepsis patent thumbnailDiagnostic for sepsis
A method of diagnosing severe sepsis prior to definitive clinical diagnosis. A pattern of gene expression that correlates strongly with a future diagnosis of severe sepsis and organ failure was identified in patients who had their blood drawn at first clinical presentation.

 Method of amplifying nucleic acid sequences patent thumbnailMethod of amplifying nucleic acid sequences
The invention is directed to methods of removing amplicons of non target and/or target nucleic acid sequences having one or more modified (e.g., methylated) nucleotides from a sample wherein the sample comprises the non target nucleic acid and a target nucleic acid sequence to be amplified.. .
Courtagen Life Sciences, Inc.


Recombinant adeno-associated vectors for targeted treatment

Novel adeno-associated virus (aav) vectors in nucleotide and amino acid forms and uses thereof are provided. The isolates show specific tropism for certain target tissues, such as blood stem cells, liver, heart and joint tissue, and may be used to transduce stem cells for introduction of genes of interest into the target tissues.
City Of Hope

Isolated polynucleotides and polypeptides, and methods of using same for improving plant properties

Provided are isolated polynucleotides which are at least 80% homologous to seq id no: 320, 1-319, 321-473, 836-1652, 1654-3221, 3225-3241, 3243-3630, 3632-4176 or 4177; and isolated polypeptides which are at least 80% homologous to seq id no: 760, 474-759, 761-770, 772-835 and 4178-4195, 4197-4213, 4215-4216, 4218-5334, 5336-5522, 5524-5754, 5756-6215, 6217, 6220-6223, 6230, 6232, 6235-6607, 6609-6614, 6620-7129 or 7130, nucleic acid constructs comprising the isolated polynucleotides, transgenic plants expressing same and methods of using same for increasing abiotic stress tolerance, yield, biomass, growth rate, vigor, oil content, fiber yield, fiber quality, and/or nitrogen use efficiency of a plant.. .
Evogene Ltd.

Cotton fibers with increased glucosamine content

An isolated nucleic acid molecule is provided comprising a nucleotide sequence which encodes a glutamine:fructose-6-phosphate amidotransferase from e. Coli which is particularly suitable for expression in cotton plant cells.
Bayer Cropscience Nv

Regulatory element for heterologous protein production in the fruiting body of filamentous fungi

The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the agaricus bisporus lectin gene.
Intrexon Corporation

Method for suppressing cell growth

Disclosed is a method for suppressing the growth of a target cell, which is not limited in the type of a target cell and the type of a protein to be expressed in the target cell and needs not any preparatory experiment for determining a codon to be contained in a protein to be expressed in a target cell. Specifically disclosed is a method for suppressing the growth of a target cell, which comprises the steps of: incorporating dna containing a region encoding a protein into the target cell, and allowing a protein encoded by the dna to be expressed in the target cell into which the dna has been incorporated.
Japan Agency For Marine-earth Science And Technology

Modulators of growth hormone receptor

The present embodiments provide methods, compounds, and compositions for treating, preventing, ameliorating a disease associated with excess growth hormone using antisense compounds oligonucleotides targeted to growth hormone receptor (ghr).. .
Ionis Pharmaceuticals, Inc.

Nucleic acid fragment binding to target protein

An object of the present invention is to develop and provide a method for efficiently producing a nucleic acid aptamer, particularly, a dna aptamer, having higher specificity and binding activity against a target substance than those of nucleic acid aptamers obtained by conventional methods. The present invention provides a transcribable or replicable nucleic acid aptamer comprising a natural nucleotide and a non-natural nucleotide having an artificial base-pairable artificial base.
Tagcyx Biotechnologies

Binding-induced dna nanomachines

The invention provides a binding-induced dna nanomachine that can be activated by proteins and nucleic acids. This new type of nanomachine hamesses specific target binding to trigger assembly of separate dna components that are otherwise unable to spontaneously assemble.
The Governors Of The University Of Alberta

Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene

The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a collagen gene, in particular, by targeting natural antisense polynucleotides of a collagen gene. The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of collagen genes..
Curna, Inc.

Compositions and methods for selective delivery of oligonucleotide molecules to cell types

The invention provides a conjugate comprising (i) a nucleic acid which is complementary to a target nucleic acid sequence and which expression prevents or reduces expression of the target nucleic acid and (ii) a selectivity agent which is capable of binding with high affinity to a receptor which can be internalised by the cell in response to the binding of said selectivity agent. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of contrast agents to the cells for diagnostic purposes..
Nlife Therapeutics, S.l.

Lentiviral-based vector and its use in directed evolution of genomic regions, genes and polynucleotides

Replication-defective lentiviral vectors are described. Using this vector, methods of directing evolution of a target polynucleotide of interest for obtaining variants of the target polynucleotide, methods to generate genetic variability by preparing a cell library, and methods to isolate and/or screen variants of a polynucleotide or variants of a protein able to impact the phenotype of a cell or to confer a desired phenotype to target cells and to identify theses polynucleotide variants or protein variants responsible for this phenotype are described..
Universite Pierre Et Marie Curie (paris 6)

Genomic sequence modification specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same

The present invention provides a method of modifying a targeted site of a double stranded dna, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded dna and a nucleic acid base converting enzyme are bonded, with the double stranded dna, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one chain of the double stranded dna in the targeted site.. .
National University Corporation Kobe University

Processing of polynucleotides

Methods and compositions for processing polynucleotides are provided according to some embodiments herein. In some embodiments, a sample is immobilized in a porous matrix, and non-polynucleotides are removed from the sample.
Bionano Genomics, Inc.

Polypeptides having xanthan degrading activity and polynucleotides encoding same

The present invention relates to isolated polypeptides having xanthan degrading activity, catalytic domains and polynucleotides encoding the polypeptides and catalytic domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides and catalytic domains..
Novozymes A/s

Glucoamylase variants and polynucleotides encoding same

The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants..
Novozymes A/s

Engineered biocatalysts useful for carbapenem synthesis

The present disclosure provides engineered pnb esterase polypeptides useful for the synthesis of the carbapenem antibiotic, imipenem. The disclosure also provides polynucleotides encoding the engineered pnb esterases, host cells capable of expressing the engineered pnb esterases, and methods of using the engineered pnb esterases in the production of imipenem..
Codexis, Inc.

Polypeptides having organophosphorous hydrolase activity

The present invention relates to isolated polypeptides having organophosphorous hydrolase activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides..
Novozymes A/s

Transaminase polypeptides

The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds..
Codexis Inc.

Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (fra) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to fra-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors.
Morphotek, Inc.

Anti-kit antibodies and uses thereof

Provided herein, in one aspect, are antibodies that immunospecifically bind to a human kit antigen comprising the fourth and/or fifth extracellular ig-like domains (that is, d4 and/or d5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit kit activity, such as ligand-induced receptor phosphorylation.
Kolltan Pharmaceuticals, Inc.

Anti-activin a antibodies and uses thereof

The disclosure provides compositions and methods relating to or derived from anti-activin a binding proteins, including antibodies. In particular embodiments, the disclosure provides fully human, humanized, and chimeric anti-activin a antibodies that bind human activin a, activin a-binding fragments and derivatives of such antibodies, and activin a-binding polypeptides comprising such fragments.
Amgen Inc.

Mrka polypeptides, antibodies, and uses thereof

The present disclosure provides mrka binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to mrka and induce opsonophagocytic killing of klebsiella (e.g., klebsiella pneumoniae). The present disclosure also provides methods of reducing klebsiella (e.g., klebsiella pneumoniae) or treating or preventing klebsiella (e.g., klebsiella pneumoniae) infection in a subject comprising administering mrka binding proteins, e.g., antibodies or antigen-binding fragments thereof, mrka polypeptides, immunogenic fragments thereof, or polynucleotides encoding mrka or immunogenic fragments thereof to the subject..
Medimmune, Llc

Factor viii chimeric proteins and uses thereof

The present invention provides a chimeric protein comprising a first polypeptide which comprises a fviii protein and a first ig constant region or a portion thereof and a second polypeptide which comprises a vwf protein comprising the d′ domain and d3 domain of vwf, a xten sequence having less than 288 amino acids in length, and a second ig constant region or a portion thereof, wherein the first polypeptide and the second polypeptide are associated with each other. The invention also includes nucleotides, vectors, host cells, methods of using the chimeric proteins..
Biogen Ma Inc.

Ribosomes with tethered subunits

An engineered ribosome that includes a tethered subunit arrangement is disclosed, in which the engineered ribosome supports translation of a sequence defined polymer. Methods for making and using the engineered ribosome are also disclosed, including a method for preparing a sequence defined polymer using the engineered ribosome and a method for preparing a sequence defined polymer using the engineered ribosome in a two-protein translation system.
Northwestern University

Viral inhibitory nucleotide sequences and vaccines

The invention relates to inhibitory nucleotide signal sequences or “ins” sequences in the genomes of lentiviruses. In particular the invention relates to the agg motif present in all viral genomes.
Institute For Advanced Study

Synthesis of bicyclic nucleosides

The present disclosure provides methods for synthesizing modified nucleosides, nucleotides, and oligonucleotides comprising at least one 2′-c-bridged bicyclic nucleotide, and to intermediates used in the process.. .
Miragen Therapeutics, Inc.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Nucleotide for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nucleotide with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2115

file did exist - file did put2923

5 - 1 - 61